133 related articles for article (PubMed ID: 22228819)
1. Fibroblast growth factor-2 is an important factor that maintains cellular immaturity and contributes to aggressiveness of osteosarcoma.
Shimizu T; Ishikawa T; Iwai S; Ueki A; Sugihara E; Onishi N; Kuninaka S; Miyamoto T; Toyama Y; Ijiri H; Mori H; Matsuzaki Y; Yaguchi T; Nishio H; Kawakami Y; Ikeda Y; Saya H
Mol Cancer Res; 2012 Mar; 10(3):454-68. PubMed ID: 22228819
[TBL] [Abstract][Full Text] [Related]
2. Induction of transforming growth factor-beta1 by basic fibroblast growth factor in rat C6 glioma cells and astrocytes is mediated by MEK/ERK signaling and AP-1 activation.
Dhandapani KM; Khan MM; Wade FM; Wakade C; Mahesh VB; Brann DW
J Neurosci Res; 2007 Apr; 85(5):1033-45. PubMed ID: 17335076
[TBL] [Abstract][Full Text] [Related]
3. HAS3-related hyaluronan enhances biological activities necessary for metastasis of osteosarcoma cells.
Tofuku K; Yokouchi M; Murayama T; Minami S; Komiya S
Int J Oncol; 2006 Jul; 29(1):175-83. PubMed ID: 16773198
[TBL] [Abstract][Full Text] [Related]
4. Activation of the RAF/mitogen-activated protein/extracellular signal-regulated kinase kinase/extracellular signal-regulated kinase pathway mediates apoptosis induced by chelerythrine in osteosarcoma.
Yang R; Piperdi S; Gorlick R
Clin Cancer Res; 2008 Oct; 14(20):6396-404. PubMed ID: 18927278
[TBL] [Abstract][Full Text] [Related]
5. Reduction of metastasis, cell invasion, and adhesion in mouse osteosarcoma by YM529/ONO-5920-induced blockade of the Ras/MEK/ERK and Ras/PI3K/Akt pathway.
Tsubaki M; Satou T; Itoh T; Imano M; Ogaki M; Yanae M; Nishida S
Toxicol Appl Pharmacol; 2012 Mar; 259(3):402-10. PubMed ID: 22326785
[TBL] [Abstract][Full Text] [Related]
6. Involvement of extracellular signal-regulated kinase activation in human osteosarcoma cell resistance to the histone deacetylase inhibitor FK228 [(1S,4S,7Z,10S,16E,21R)-7-ethylidene-4,21-bis(propan-2-yl)-2-oxa-12,13-dithia-5,8,20,23-tetraazabicyclo[8.7.6]tricos-16-ene-3,6,9,19,22-pentone].
Matsubara H; Watanabe M; Imai T; Yui Y; Mizushima Y; Hiraumi Y; Kamitsuji Y; Watanabe K; Nishijo K; Toguchida J; Nakahata T; Adachi S
J Pharmacol Exp Ther; 2009 Mar; 328(3):839-48. PubMed ID: 19073909
[TBL] [Abstract][Full Text] [Related]
7. Stromal cell-derived factor-1/CXCR4 enhanced motility of human osteosarcoma cells involves MEK1/2, ERK and NF-kappaB-dependent pathways.
Huang CY; Lee CY; Chen MY; Yang WH; Chen YH; Chang CH; Hsu HC; Fong YC; Tang CH
J Cell Physiol; 2009 Oct; 221(1):204-12. PubMed ID: 19496172
[TBL] [Abstract][Full Text] [Related]
8. RhoA GTPase inactivation by statins induces osteosarcoma cell apoptosis by inhibiting p42/p44-MAPKs-Bcl-2 signaling independently of BMP-2 and cell differentiation.
Fromigué O; Haÿ E; Modrowski D; Bouvet S; Jacquel A; Auberger P; Marie PJ
Cell Death Differ; 2006 Nov; 13(11):1845-56. PubMed ID: 16470222
[TBL] [Abstract][Full Text] [Related]
9. Fibroblast growth factor-2 is an immediate-early gene induced by mechanical stress in osteogenic cells.
Li CF; Hughes-Fulford M
J Bone Miner Res; 2006 Jun; 21(6):946-55. PubMed ID: 16753025
[TBL] [Abstract][Full Text] [Related]
10. Parathyroid hormone affects the fibroblast growth factor-proteoglycan signaling axis to regulate osteosarcoma cell migration.
Datsis GA; Berdiaki A; Nikitovic D; Mytilineou M; Katonis P; Karamanos NK; Tzanakakis GN
FEBS J; 2011 Oct; 278(19):3782-92. PubMed ID: 21834878
[TBL] [Abstract][Full Text] [Related]
11. Disruption of fibroblast growth factor signal pathway inhibits the growth of synovial sarcomas: potential application of signal inhibitors to molecular target therapy.
Ishibe T; Nakayama T; Okamoto T; Aoyama T; Nishijo K; Shibata KR; Shima Y; Nagayama S; Katagiri T; Nakamura Y; Nakamura T; Toguchida J
Clin Cancer Res; 2005 Apr; 11(7):2702-12. PubMed ID: 15814652
[TBL] [Abstract][Full Text] [Related]
12. SB-431542 and Gleevec inhibit transforming growth factor-beta-induced proliferation of human osteosarcoma cells.
Matsuyama S; Iwadate M; Kondo M; Saitoh M; Hanyu A; Shimizu K; Aburatani H; Mishima HK; Imamura T; Miyazono K; Miyazawa K
Cancer Res; 2003 Nov; 63(22):7791-8. PubMed ID: 14633705
[TBL] [Abstract][Full Text] [Related]
13. Reduced syndecan-1 expression stimulates heparin-binding growth factor-mediated invasion in ovarian cancer cells in a urokinase-independent mechanism.
Matsuzaki H; Kobayashi H; Yagyu T; Wakahara K; Kondo T; Kurita N; Sekino H; Inagaki K; Suzuki M; Kanayama N; Terao T
Oncol Rep; 2005 Aug; 14(2):449-57. PubMed ID: 16012729
[TBL] [Abstract][Full Text] [Related]
14. Osteogenic potential of murine osteosarcoma cells: comparison of bone-specific gene expression in in vitro and in vivo conditions.
Gerstenfeld LC; Uporova T; Schmidt J; Strauss PG; Shih SD; Huang LF; Gundberg C; Mizuno S; Glowacki J
Lab Invest; 1996 May; 74(5):895-906. PubMed ID: 8642785
[TBL] [Abstract][Full Text] [Related]
15. RANKL directly induces bone morphogenetic protein-2 expression in RANK-expressing POS-1 osteosarcoma cells.
Wittrant Y; Lamoureux F; Mori K; Riet A; Kamijo A; Heymann D; Redini F
Int J Oncol; 2006 Jan; 28(1):261-9. PubMed ID: 16328004
[TBL] [Abstract][Full Text] [Related]
16. A novel collagen-binding peptide promotes osteogenic differentiation via Ca2+/calmodulin-dependent protein kinase II/ERK/AP-1 signaling pathway in human bone marrow-derived mesenchymal stem cells.
Shin MK; Kim MK; Bae YS; Jo I; Lee SJ; Chung CP; Park YJ; Min do S
Cell Signal; 2008 Apr; 20(4):613-24. PubMed ID: 18248957
[TBL] [Abstract][Full Text] [Related]
17. Potent antiproliferative effects of resveratrol on human osteosarcoma SJSA1 cells: Novel cellular mechanisms involving the ERKs/p53 cascade.
Alkhalaf M; Jaffal S
Free Radic Biol Med; 2006 Jul; 41(2):318-25. PubMed ID: 16814113
[TBL] [Abstract][Full Text] [Related]
18. Blockade of the Ras/MEK/ERK and Ras/PI3K/Akt pathways by statins reduces the expression of bFGF, HGF, and TGF-β as angiogenic factors in mouse osteosarcoma.
Tsubaki M; Yamazoe Y; Yanae M; Satou T; Itoh T; Kaneko J; Kidera Y; Moriyama K; Nishida S
Cytokine; 2011 Apr; 54(1):100-7. PubMed ID: 21292498
[TBL] [Abstract][Full Text] [Related]
19. The inhibition of RANKL/RANK signaling by osteoprotegerin suppresses bone invasion by oral squamous cell carcinoma cells.
Shin M; Matsuo K; Tada T; Fukushima H; Furuta H; Ozeki S; Kadowaki T; Yamamoto K; Okamoto M; Jimi E
Carcinogenesis; 2011 Nov; 32(11):1634-40. PubMed ID: 21890459
[TBL] [Abstract][Full Text] [Related]
20. Histone demethylase JMJD2B and JMJD2C induce fibroblast growth factor 2: mediated tumorigenesis of osteosarcoma.
Li X; Dong S
Med Oncol; 2015 Mar; 32(3):53. PubMed ID: 25636512
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
